

**Table 4. Risedronate (Actonel) for Paget's Disease**

Study	Regimens	Duration Treatment	N	Endpoints	Results
Miller et al <sup>7</sup>	Risedronate: 30 mg/d Etidronate: 400 mg/d	Risedronate: 2 months Etidronate: 6 months	123	Serum alkaline phosphatase (SAP), serum bone specific alkaline phosphatase, and urinary deoxypyridinoline were monitored for 12-18 months	Serum alkaline phosphatase normalized by month 12 in 73% of risedronate patients and 15% of etidronate patients (P < 0.001). Relapse rates were 3% for the risedronate group and 15% in the etidronate group (P < 0.05). The sample size was small.
Singer et al <sup>8</sup>	Risedronate: 30 mg/d	8 weeks; followed for additional 16 weeks	13	SAP	Risedronate produced a mean decrease from baseline in SAP of 77% by week 24 (no P-value). However, the sample size was very small.